Every single day, the DNA of each cell in the human body is mutated thousands of times, even in absence of oncogenes or extreme radiation. Many of these mutations could lead to cancer and, finally, death. To fight this, multicellular organisms have evolved an efficient control system with the tumor-suppressor protein p53 as the central element. An intact p53 network ensures that DNA damage is detected early on. The importance of p53 for preventing cancer is highlighted by the fact that p53 is inactivated in more than 50 % of all human tumors. Thus, for good reason, p53 is one of the most intensively studied proteins. Despite the great effort that has been made to characterize this protein, the complex function and the structural properties of p53 are still only partially known. This review highlights basic concepts and recent progress in understanding the structure and regulation of p53, focusing on emerging new mechanistic and therapeutic concepts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/anie.200600611 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of Knowledge in Practice.
Am J Occup Ther
January 2025
Nicole Quint, PhD, DrOT, OTR/L, is Professor and Program Director, Dual Degree DrOT/PhD and DrOT Programs, Nova Southeastern University, Ft. Lauderdale, FL;
Given the number of occupational therapy doctorate (OTD) programs and graduates with professional doctoral degrees, the concept of practice scholarship is increasingly important. The scholarly work of occupational therapy practitioners guided by a research model is appropriate for those who have trained as researchers or OTD students and practitioners receiving mentorship from occupational therapy research scientists. A research model of scholarship may not fit the scholarly work of most occupational therapy practitioners with an OTD.
View Article and Find Full Text PDFPatients' Willingness to Perform Self-Wound Care: A Cross-sectional Study in the Primary Healthcare Sector in Singapore.
Adv Skin Wound Care
January 2025
Ling Jia Goh, MClin Res, MHA, Adv Dip (CCNC), BHS (Nursing), Dip (Nursing with Merit), is Nurse Manager (Research), Department of Nursing, National Healthcare Group Polyclinics, Singapore. Xiaoli Zhu, MN, RN, is Wound Care Senior Nurse Clinician, National Healthcare Group Polyclinics, and PhD candidate, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
Background: Patient adherence to performing self-wound care (SWC) has a direct influence on the success of telewound care, a healthcare delivery mode that emerged in 2016 in National Healthcare Group Polyclinics in Singapore to relieve the healthcare burden. This mode of delivery was useful during the pandemic, when nonurgent face-to-face visits were switched to the use of telecommunications for consultation. Telewound care requires that patients be willing to perform wound care on their own; however, whether patients are willing to do so remains unknown.
View Article and Find Full Text PDFEstablishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology.
Neuro Oncol
January 2025
Childhood Cancer & Cell Death team (C3 team), Consortium South-ROCK, LabEx DEVweCAN, Institut Convergence Plascan, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, 69008 Lyon, France.
Background: Brain tumors are the deadliest solid tumors in children and adolescents. Most of these tumors are glial in origin and exhibit strong heterogeneity, hampering the development of effective therapeutic strategies. In the past decades, patient-derived tumor organoids (PDT-O) have emerged as powerful tools for modeling tumoral cell diversity and dynamics, and they could then help defining new therapeutic options for pediatric brain tumors.
View Article and Find Full Text PDFClinical Pharmacokinetics of Antitubercular Drugs in the Overweight and Obese Population: Implications for Dosage Adjustments.
Clin Pharmacokinet
January 2025
Department of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
The rise in global obesity prevalence has increased the need to understand the pharmacokinetics of drugs in overweight and obese individuals. Tuberculosis remains a significant health challenge, and its treatment outcomes can be influenced by the pharmacokinetic profiles of antitubercular agents. This literature review aims to point out the clinical pharmacokinetics of antitubercular drugs in the overweight and obese patient population, highlighting considerations for potential dosage adjustments.
View Article and Find Full Text PDFExploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives.
ACS Appl Bio Mater
January 2025
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad 500037, India.
Immunotherapy is a cutting-edge approach that leverages sophisticated technology to target tumor-specific antibodies and modulate the immune system to eradicate cancer and enhance patients' quality of life. Bioinformatics and genetic science advancements have made it possible to diagnose and treat cancer patients using immunotherapy technology. However, current immunotherapies against cancer have limited clinical benefits due to cancer-associated antigens, which often fail to interact with immune cells and exhibit insufficient therapeutic targeting with unintended side effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!